共 20 个 OTC 专论产品
| 序号 | NDC编码 | 商品名 | 剂型 | 上市日期 | 专论编号 |
|---|---|---|---|---|---|
| 1 | 85398-023-01 | Hermon bed sore and pressure sore cream | CREAM | 2026-03-24 | M004 |
| 2 | 85398-036-01 | Hermon Jock Itch Ringworm Athletes Foot Cream | CREAM | 2026-09-23 | M005 |
| 3 | 85398-002-01 | Tinea Versicolor Treatment Cream | CREAM | 2025-05-12 | M005 |
| 4 | 85398-003-01 | Tinea Versicolor Treatment Bar | SOAP | 2025-05-12 | M005 |
| 5 | 85398-004-01 | Tinea Versicolor Treatment Kit | KIT | 2025-05-15 | M005 |
| 6 | 85398-006-01 | Athlete Foot Cream | CREAM | 2025-08-18 | M005 |
| 7 | 85398-007-01 | Athlete Foot Medicated bar | SOAP | 2025-08-18 | M005 |
| 8 | 85398-008-01 | Athlete Foot Treatment Kit | KIT | 2025-08-20 | M005 |
| 9 | 85398-012-01 | Clotrimazole antifungal treatment kit | KIT | 2025-08-31 | M005 |
| 10 | 85398-010-01 | Hermon Clotrimazole antifungal treatment cream | CREAM | 2025-08-31 | M005 |
| 11 | 85398-011-01 | Hermon Clotrimazole antifungal soap. bar | SOAP | 2025-08-31 | M005 |
| 12 | 85398-016-01 | Hermon Antifungal Jock Itch Body Wash | GEL | 2025-10-31 | M005 |
| 13 | 85398-013-01 | Hermon Balanitis Cream | CREAM | 2025-09-15 | M005 |
| 14 | 85398-014-01 | Hermon Balanitis relief kit | KIT | 2025-09-17 | M005 |
| 15 | 85398-020-02 | Hermon Antifungal Soap. 4 packs | SOAP | 2025-11-25 | M005 |
| 16 | 85398-017-01 | Initial Drug Listing - Hermon Athletes Foot 1% Tolnaftate Cream | CREAM | 2025-10-31 | M005 |
| 17 | 85398-018-01 | Hermon Athletes foot Tolnaftate 1% kit | KIT | 2025-10-31 | M005 |
| 18 | 85398-019-02 | Hermon Antifungal Soap. | SOAP | 2025-11-07 | M005 |
| 19 | 85398-001-01 | Folliculitis Cream | CREAM | 2025-04-20 | M006 |
| 20 | 85398-009-01 | Hermon Folliculitis Shampoo. | SHAMPOO | 2025-08-31 | M032 |
标准化流程确保专论判定准确、文件齐备、标签合规,缩短整体办理周期。
提交配方表、活性成分、宣称用途及现有检测报告,进行初步合规评估。
比对21 CFR对应专论条款,确认产品归属类别及GRASE活性成分浓度范围。
指定美国代理人,完成FDA药品生产设施注册与产品列名申请。
按21 CFR 201.66制作Drug Facts标签,核对警示语、适应症与使用方法。
提供完整合规文件包,协助清关申报与上市后持续合规维护。
关于 OTC 化妆品出口美国合规的常见疑问解答。
微信号:KOL123567
添加时请备注「公司-职务-姓名」
优先安排资深法规专家 1 对 1 对接
我们已收到您的合规咨询需求
资深 FDA 法规顾问将在 1 个工作日内与您联系